Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loxapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 known ✓ | P21917 | 7/20 | 0.95 |
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.95 |
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 0.95 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.95 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.95 |
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.95 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.95 |
| ▸ | HRH1 | P35367 | 4/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.95 |
| ▸ | HRH2 | P25021 | 3/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.95 |
| ▸ | HTR1A | P08908 | 3/20 | 0.95 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.95 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.95 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.95 |
| ▸ | DRD1 | P21728 | 3/20 | 0.95 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.95 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loxapine SCHEMBL19386241 | 0.98 | HRH4 (1.00) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL29482385 | 0.98 | HRH4 (1.00) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL94146 | 0.98 | HRH4 (1.00) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL30324780 | 0.98 | HRH4 (1.00) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL29374082 | 0.98 | HRH4 (1.00) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL41625 | 0.96 | HRH4 (0.98) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL30903930 | 0.96 | HRH4 (0.98) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL4164270 | 0.96 | HRH4 (0.98) | HRH4DRD4DRD2DRD3CHRM1 | |
| SCHEMBL7410631 | 0.89 | HRH4 (0.84) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL41644 | 0.89 | LMNA (0.82) | HRH4DRD4DRD2DRD3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3459535-B1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2020-08-12 | — | — | EP | disclosed |
| US-20200155491-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2020-05-21 | — | — | US | disclosed |
| US-10463640-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2019-11-05 | — | — | US | disclosed |
| US-10441558-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2019-10-15 | — | — | US | disclosed |
| US-10322101-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2019-06-18 | — | — | US | disclosed |
| EP-3459535-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | Pharnext (FR) | 2019-03-27 | — | — | EP | disclosed |
| US-20180360785-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2018-12-20 | — | — | US | disclosed |
| US-20180338969-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2018-11-29 | — | — | US | disclosed |
| EP-2609916-B1 | New therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2018-11-07 | — | — | EP | disclosed |
| US-20180250289-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2018-09-06 | — | — | US | disclosed |
| US-20150157626-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | NEOVACS S.A. (FR) | 2015-06-11 | — | — | US | disclosed |
| US-8992891-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2015-03-31 | — | — | US | disclosed |
| CN-101883561-B | Novel therapeutic methods for treating CMT and related diseases | PHARNEXT | 2014-07-30 | — | — | CN | disclosed |
| EP-2609916-A1 | New therapeutic approaches for treating CMT and related disorders | Pharnext (FR) | 2013-07-03 | — | — | EP | disclosed |
| EP-2211846-B1 | New therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2013-02-27 | — | — | EP | disclosed |
| US-20100310641-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2010-12-09 | — | — | US | disclosed |
| CN-101883561-A | Novel therapeutic methods for treating CMT and related diseases | PHARNEXT | 2010-11-10 | — | — | CN | disclosed |
| EP-2211846-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | Pharnext (FR) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009068668-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2009-06-04 | — | — | WO | disclosed |